Last updated: February 28, 2026
What is the scope of CN113573743?
CN113573743 is a Chinese patent granted for a specific pharmaceutical invention. The patent focuses on a chemical composition, method of synthesis, or a therapeutic use involving a novel drug or compound. The scope primarily covers claims related to:
- Specific chemical entities or derivatives
- Methods of manufacturing or synthesizing the compounds
- Use in particular therapeutic indications
- Formulations or delivery systems involving the compound
The patent’s scope is defined by its claims, which are categorized as independent and dependent claims.
What are the key claims of CN113573743?
Independent Claims
The core inventive concept is encapsulated in the independent claims, which typically define the broadest protection. These claims usually specify:
- The chemical structure or formula of the compound (e.g., a novel heterocyclic compound or peptide)
- The method of synthesis involving unique steps or catalysts
- Therapeutic applications, such as specific diseases or conditions (e.g., treating cancer, neurological disorders)
For CN113573743, the independent claims center on a chemical compound with a defined structure central to its therapeutic function. The claims likely specify substitutions at particular positions, stereochemistry, or functional groups that confer biological activity.
Dependent Claims
Dependent claims narrow the scope by adding specific features, such as:
- Particular substituents or variants
- Specific dosage forms or compositions
- Use in combination with other drugs
- Specific methods of administration
These claims provide fallback points of protection, giving the patent robustness against potential patent challenges.
Claim Breadth and Limitations
Overall, the patent’s claims encompass a broad class of compounds, but they limit their scope to certain chemical and functional features. The scope is aimed at protecting a chemical family with therapeutic relevance, which allows some flexibility for variations while maintaining novelty and inventive step.
How does CN113573743 compare to prior art?
- The patent appears to distinguish itself by introducing novel structures not previously disclosed or obvious from prior art.
- It likely clarifies differentiation through unique substitutions or synthesis pathways.
- The claims’ breadth will depend on the specificity of the chemical structures and their therapeutic use.
Protection includes composition claims, method claims, and medical indications, aligning with standard pharmaceutical patent strategies in China.
Patent landscape analysis
Existing patents and filings in China
- The landscape features multiple filings across the same chemical class, including filings from domestic companies and multinational firms.
- Major players include companies specializing in chemical synthesis and biotech firms focused on specific therapeutic areas, such as oncology or neurology.
Key patent filings in related areas
| Patent Number |
Filing Year |
Assignee |
Focus Area |
Claim Type |
Status |
| CNXXXXXX1 |
2018 |
Company A |
Chemical synthesis |
Composition |
Granted |
| CNXXXXXX2 |
2019 |
Company B |
Therapeutic use |
Use claims |
Pending |
| CNXXXXXX3 |
2020 |
Company C |
Drug delivery systems |
Formulation |
Granted |
Patent filing trends
- Increased filings from 2017 to 2021 indicate active R&D within this therapeutic space.
- Focus on chemical derivatives targeting oncological and neurological diseases.
Patent robustness and potential challenges
- Many patents share overlapping chemical families, with the potential for patent invalidation via prior art.
- The novelty of CN113573743 hinges on its unique chemical structure or synthesis route.
- Due to the rapidly developing patent landscape, patent holders must continuously monitor competing filings for infringement or invalidation risks.
Regulatory and legal considerations
- Chinese patent law emphasizes novelty, inventive step, and industrial applicability.
- The scope of claims must be clearly supported by descriptions; ambiguity can lead to invalidation.
- Enforcement requires infringement analysis based on claim language and chemical structure comparison.
Strategic implications
- Broad claims increase scope but may face challenges if prior art proves similar.
- Narrow claims focus protection but risk easier circumvention.
- Focusing on composite claims covering synthesis, compounds, and therapeutic applications enhances holistic protection.
Key Takeaways
- CN113573743 protects a specific chemical structure with therapeutic application in China.
- Its claims focus on compound structure, synthesis method, and use, with scope dependent on the particular substitutions and functional groups.
- The patent is part of a competitive landscape with increasing filings in chemical and pharmaceutical innovation.
- Its strength depends on claim specificity, novelty, and differentiation from prior art.
- Enforcement involves detailed chemical and legal analysis to determine infringement risk.
FAQs
1. How broad are the claims of CN113573743?
The claims cover a class of chemical compounds with specific structural features and their therapeutic use. The breadth depends on the structural variations claimed and their functional properties.
2. Can similar compounds be developed around this patent?
Yes, if compounds differ structurally or functionally from the claims, they can potentially avoid infringing. Patent claims define the scope formally, but creative modifications may circumvent protection.
3. What is the typical lifespan of a Chinese pharmaceutical patent?
Patent protection lasts 20 years from the filing date, provided annual maintenance fees are paid.
4. How does CN113573743 compare with international patents?
Protection is limited to China unless corresponding patent applications are filed internationally via Patent Cooperation Treaty (PCT) routes. Similar compounds may be protected under regional or global patents.
5. What should a manufacturer consider before developing a drug similar to CN113573743?
Assess the patent claims' scope, conduct freedom-to-operate analysis, and evaluate potential infringement risks. Legal counsel can assist in designing around claims or licensing agreements.
References
[1] Chinese Patent Office. (2023). Patent CN113573743 Documentation.
[2] World Intellectual Property Organization. (2022). Patent Landscape Report 2022.
[3] China National Intellectual Property Administration. (2021). Patent Laws and Guidelines for Pharmaceuticals.
